spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  RNAi therapeutics 

 HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2022
Eleven Therapeutics Announces $22 Million in Seed Funding
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jul 2021
Sirnaomics Secures $105 Million in Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Jul 2019
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part Of A Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2019
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Sep 2018
Dr. Dmitry Samarsky Joins Sirnaomics Senior Management Team as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Dec 2017
Sirnaomics' Leading siRNA Therapeutic Candidate, STP705, Granted Orphan Designation for Treatment of Cholangiocarcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Apr 2017
RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Sep 2016
Amgen And Arrowhead Pharmaceuticals Announce Two Cardiovascular Collaborations
Biopharmaceuticals Licensing
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jun 2015
Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jun 2014
Solstice Biologics Appoints Dr. Lou Tartaglia as President, Chief Executive Officer; John Borgeson Joins as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Feb 2014
Ambrx Appoints Barry Greene to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 6 Jan 2014
Tekmira Announces Strategic Reorganization to Strengthen Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2013
Arrowhead Promotes David Lewis to Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2013
Tekmira Strengthens Development Team With Appointment of Dr. Mark Kowalski as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2013
Dicerna Secures $60 Million in Oversubscribed Series C Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 4 Jan 2013
Solstice Biologics Secures $18 Million Series A; Licenses RNAi Delivery Technology from UC San Diego
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Jun 2012
Alnylam Expands and Develops Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Mar 2012
Tekmira Files Motion to Dismiss in Patent Infringement Suit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 10 Feb 2012
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2011
Tekmira Reports Expected Answer and Amended Counterclaim is Filed by Alnylam
Biopharmaceuticals Litigation
 HSMN NewsFeed - 29 Jun 2011
Alnylam Files Answer and Counterclaim Related to Tekmira Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 13 Jun 2011
Alnylam Appoints Akshay Vaishnaw as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2011
Apthera and RXi Pharmaceuticals Announce Definitive Merger Agreement
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 29 Mar 2011
PhaseRx Appoints Richard P. Rieger Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Alnylam Elects Marsha Fanucci to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Oct 2010
Dicerna Pharmaceuticals Announces Second Close of Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2010
Tekmira Pharmaceuticals Strengthens Management Team With Addition of Paul Brennan as Senior Vice President, Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2010
BIND Biosciences Secures $12.4 Million Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 29 Jun 2010
BIND Biosciences Appoints Ed Schnipper, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jun 2010
Philips and RXi Pharmaceuticals Sign Agreement to Jointly Research Innovative Image-Guided Therapy Concepts Based on RNAi
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 2 Jun 2010
Alnylam Strengthens Management Team with New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 May 2010
Dicerna Names Douglas Fambrough as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2010
Silence Therapeutics Appoints Max Herrmann as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jan 2010
BIND Biosciences, Inc. closes $11 M Series C financing round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 16 Dec 2009
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 9 Sep 2009
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Apr 2009
RXi Pharmaceuticals Appoints Richard Chin, M.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Apr 2009
RXi Pharmaceuticals Announces an Addition, Promotions Among Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Feb 2009
Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 2 Oct 2008
Intradigm Raises $18.5 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
Expression Genetics Inc., Specializing in DNA/RNAi Delivery and Therapeutics, Completes $12M Series B Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 4 Aug 2008
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jun 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Completion of Business Combination
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 May 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2008
Celera Grants License to Merck & Co., Inc. for Cancer Targets
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Dec 2007
CytRx Announces Management Promotions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2007
Alnylam Appoints Barry Greene President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2007
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Nov 2007
Alnylam Expands Management Team with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2007
Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2007
Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery
Biopharmaceuticals Personnel Drug Delivery
 HSMN NewsFeed - 24 Sep 2007
CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
Biopharmaceuticals Neurology Wound Care
 HSMN NewsFeed - 19 Sep 2007
Alnylam Announces the Termination of its Collaboration with Merck & Co., Inc.
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2007
CytRx Names Mitchell K. Fogelman Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2007
RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2007
CytRx Subsidiary RXi Pharmaceuticals Names Life Science Veteran Stephen J. DiPalma Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Sep 2007
Quark Pharmaceuticals Appoints New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jul 2007
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations with RNAi Therapeutics for CNS Diseases
Biopharmaceuticals Devices Drug Delivery Neurology
 HSMN NewsFeed - 24 Jul 2007
Alnylam Expands Management Team with New Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2007
Roche and Alnylam Form Major Alliance on RNAi Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 26 Jun 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Dmitry Samarsky, Ph.D., as Vice President of Technology Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2007
Alnylam Initiates Phase II Clinical Trial to Evaluate Safety and Anti-viral Efficacy of ALN-RSV01 in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2007
Intradigm Announces Addition of Samuel Zalipsky to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2007
CytRx Names Shi Chung Ng, Ph.D., Senior Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2007
CytRx Provides Operational Update
Biopharmaceuticals Neurology
 HSMN NewsFeed - 17 Apr 2007
Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
Insert Therapeutics Signs New Partnership with R&D Biopharmaceuticals
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Alnylam Announces Key Product and Business Goals for 2007
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2006
Alnylam Initiates Clinical Program to Evaluate Anti-Viral Activity for ALN-RSV01, an RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2006
Tacere Therapeutics Appoints Vice President, Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2006
CytRx's Arimoclomol Granted Orphan Drug Designation in European Union for Treatment of ALS
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 26 Oct 2006
Arrowhead Subsidiary, Insert Therapeutics, Inc., Raises $10 Million in Private Equity Financing
Biopharmaceuticals Drug Delivery Venture Capital
 HSMN NewsFeed - 12 Oct 2006
Arrowhead Subsidiary, Insert Therapeutics, to Hire Pharmaceutical Executive as Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 29 Sep 2006
Alnylam Announces Management Transition Plan in Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Sep 2006
Biogen Idec and Alnylam Form Alliance to Discover and Develop Therapeutics for the Potential Treatment of Progressive Multifocal Leukoencephalopathy (PML)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 May 2006
Alnylam Grants Bioneer License to Kreutzer-Limmer Patents for the RNA Interference (RNAi) Research Products Market
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 33

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 33 additional stories matching:
RNAi therapeutics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.